Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM

Silvant Capital Management LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. MassMutual Private Wealth & Trust FSB grew its stake in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares in the last quarter. V Square Quantitative Management LLC raised its position in shares of DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares in the last quarter. Essex Financial Services Inc. raised its position in shares of DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares in the last quarter. Keel Point LLC lifted its holdings in shares of DexCom by 3.1% during the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after acquiring an additional 193 shares during the period. Finally, Integrated Wealth Concepts LLC lifted its holdings in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Mizuho increased their price target on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Royal Bank Of Canada boosted their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Citigroup restated a “buy” rating and set a $88.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. TD Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Trading Up 0.4%

DXCM opened at $90.22 on Friday. The company’s 50 day moving average is $77.15 and its 200-day moving average is $70.79. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.96. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $34.05 billion, a P/E ratio of 35.66, a PEG ratio of 1.52 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 EPS. Equities research analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the sale, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,035 shares of company stock worth $5,446,673. Corporate insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.